TXMD

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2011, for AMHN, Inc. (referred to in the prompt metadata as Therapeuticsmd, Inc., though the filing identifies the issuer as AMHN, Inc.). The Company is a smaller reporting company incorporated in Nevada. During the quarter, the Company ceased operations of its primary subsidiaries, America's Minority Health Network, Inc. and Spectrum Health Network, Inc., classifying them as discontinued operations following defaults on secured promissory notes and the transfer of assets to the lender, Seatac Digital Resources, Inc.

Key Financial Metrics

Debt and Liquidity: As of March 31, 2011, the Company held $994 in cash. Total liabilities were $295,101, consisting primarily of demand promissory notes ($239,000) and accounts payable ($14,421). The Company has a significant accumulated deficit of $(1,972,003).

Material Changes vs. Prior Period

• Net Income Reversal: The Company reported a net income of $613,445 in Q1 2011 compared to a net loss of $(347,392) in Q1 2010. This swing is entirely attributable to a $705,668 gain on the disposal of discontinued operations (Spectrum Health Network), which offset operating losses.
• Operating Expenses: General and administrative expenses for continuing operations decreased significantly to $41,737 in Q1 2011 from $130,014 in Q1 2010, largely due to the termination of investor and public relations consulting fees.
• Debt Restructuring: The Company satisfied a $543,531 secured promissory note to Seatac by transferring the collateral (Spectrum Health Network shares) to the lender. This removed significant liabilities from the balance sheet but resulted in the loss of the operating subsidiary.
• Management Change: Following the default and transfer of assets, the sole officer and director, Robert Cambridge, resigned. Jeffrey D. Howes was elected as the new sole officer and director.

Outlook, Risks, and Unusual Items

• Going Concern: The filing explicitly states there is substantial doubt about the Company's ability to continue as a going concern. The Company has no revenue from continuing operations and relies on loans from shareholders to fund operations.
• Unusual Items: The reported net income is non-recurring and driven by the accounting gain from debt forgiveness via asset transfer (discontinued operations), not operational profitability. Continuing operations remain loss-making.
• Subsequent Events:
  • Convertible Notes: On April 18, 2011, a $210,000 demand note was exchanged for two convertible promissory notes totaling $210,000 at 6% interest, convertible at $0.0105 per share.
  • Acquisition Intent: On May 18, 2011, the Company entered a non-binding Letter of Intent to acquire vitaMedMD, LLC, a specialty pharmaceutical company, with a definitive agreement targeted for June 30, 2011.
  • Licensing: The Company secured a license to sell Spectrum's digital media network products in the southeastern U.S. for a 30% commission, though it no longer owns the network.
• Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2011.

Investor Verification Checklist

• Revenue Reality: Verify if the licensing agreement with Spectrum (30% commission) has generated any actual revenue, as continuing operations currently show $0 revenue.
• Capital Sufficiency: Confirm the Company's ability to fund operations given the $994 cash balance and $295,101 in liabilities without immediate equity infusion.
• vitaMedMD Acquisition: Assess the status of the non-binding Letter of Intent with vitaMedMD, LLC, as this is the primary stated path to future profitability.
• Dilution Risk: Review the terms of the new convertible notes ($210,000 principal) and the potential issuance of shares at $0.0105 per share, which could significantly dilute existing shareholders.
• Legal Standing: Verify that the transfer of Spectrum and America's Minority Health Network to Seatac has fully resolved all associated litigation or creditor claims.